New York Existence Snaps Up Group Existence & Incapacity Coverage Small business From Cigna For $6.3B

Cigna on Dec. 31 introduced the completion of the sale of its Group Existence and Incapacity Insurance policies Company to mutual everyday living insurer New York Existence for $6.3 billion. Shares of the mutual everyday living coverage company rose 2% at the close on Thursday.

Previously on Dec.18, 2019, Cigna (CI) disclosed the acquisition could probably include 3,000 staff members, above nine million prospects, and strengthen New York Life’s portfolio of strategic businesses, supporting the main retail lifetime insurance franchise and bolstering the company’s money energy. It was also stated that the new organization would be rebranded as New York Lifestyle Group Reward Options.

Cigna will use the sale proceeds toward share repurchase and reimbursement of personal debt in 2020. The board elevated the company’s share repurchase authority by $3 billion to $4 billion. The organization expects the transaction to be neutral to EPS in 2020 and modestly accretive to EPS in 2021.

New York Life and Cigna have also inked a multi-calendar year partnership to deliver distinguished, cohesive health and group gain methods for purchasers and prospects.

New York Lifetime Team Advantage Alternatives will operate inside of New York Life’s portfolio of strategic organizations, which include Group Membership Association, Institutional Annuities, Institutional Existence, New York Everyday living Immediate, and Seguros Monterrey New York Lifetime, amid other folks.

“We are excited to welcome to New York Everyday living our new personnel and the millions of new consumer relationships that we will attain through this milestone transaction. We look forward to constructing on our main group advantage alternatives market place in the a long time ahead,” mentioned New York Lifetime CEO Ted Mathas.

Mizuho analyst Ann Hynes lifted the price target on the inventory to $229 (a 10% upside prospective) from $220 on Dec. 18 and reiterated a Invest in score. Hynes believes clinical labs, contract investigation businesses and acute treatment have the greatest earnings visibility likely into 2021.

From the rest of the Avenue, the inventory scores an analyst consensus of a Robust Purchase centered on 13 Buys and 1 Hold. The average analyst price tag concentrate on of $253.36 implies upside probable of 21.7% to current ranges. (See CI inventory investigation on TipRanks)